exemestane / Generic mfg.  >>  Phase 2
Welcome,         Profile    Billing    Logout  

66 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
exemestane / Generic mfg.
ACTRN12605000416695: IBCSG 24-02 / BIG 2-02: Suppression of Ovarian Function Trial

Active, not recruiting
2
3000
 
Breast Cancer Trials, Breast Cancer Trials
Adjuvant Breast Cancer
 
 
ChiCTR-ONC-13003946: A Phase II clinical study of Goserelin combine with Exemestane in premenopausal women with metastatic breast cancer

Completed
2
30
 
Goserelin 3.6mg/Month combine with Exemestane 25mg Qd
Department of Medical Oncology, Cancer Institute/Hospital, CAMS and PUMC; Level of the institution：, Department of Medical Oncology, Cancer Institute/Hospital, CAMS and PUMC
breast cancer
 
 
2014-005126-35: This multicenter, randomized, double-blind, phase II study aims to show improvement in the rate of mucositis/stomatitis (WHO´s OTS) grade 2-4 at 12 weeks after start of treatment by comparing a conventional dosing approach starting with 10 mg at first dose versus a dose-escalating schema starting with a low dose over 21 days in patients receiving everolimus in combination with exemestane for treatment of metastatic breast cancer.

Ongoing
2
156
Europe
Afinitor, RAD001, Tablet, Afinitor
GBG Forschungs GmbH, GBG Forschungs GmbH, Novartis Pharma GmbH
Advance Breast cancer under endocrine treatment Fortgeschrittener Brustkrebs unter endokriner Behandlung, Advance Breast cancer under endocrine treatment Fortgeschrittener Brustkrebs unter endokriner Behandlung, Diseases [C] - Cancer [C04]
 
 
2004-001103-35: Exemestane in Advanced or Recurrent Endometrial Carcinoma.A multicentre non-randomized Phase II study

Ongoing
2
25
Europe
Exemestan,
Nordic Society for Gynecologic Oncology
Advanced or recurrent endometrial carcinoma
 
 
2005-001698-89: Molecular profiling of postmenopausal women with breast cancer on neoadjuvant exemestane or tamoxifen

Ongoing
2
100
Europe
Exemestane, Tamoxifen, Aromasin, Tamoxifen, Exemestane 25mg Film-coated Tablets, Tamoxifen Tablets BP 20mg, Exemestane 25mg Film-coated Tablets, Tamoxifen Tablets BP 20mg
Cambridge University Hospitals NHS Foundation Trust, None
Early or locally advanced breast cancer
 
 
2008-004169-25: Phase II study of Exemestane dose intensification (150 mg daily) in postmenopausal patients with advanced breast cancer progressing under standard dose Exe (25 mg daily) given as adjuvant or palliative therapy

Ongoing
2
76
Europe
AROMASIN*120CPR RIV 25MG, AROMASIN*120CPR RIV 25MG
ISTITUTO EUROPEO DI ONCOLOGIA
metastatic breast cancer
 
 
2010-024216-34: Neoadjuvant Endocrine Treatment +/- Bevacizumab in postmenopausal Patients with Operable Primary, HER2-neu negative Breast Cancer (including Lobular Cancer) (I) not suitable for Chemotherapy or (II) unlikely to respond to Chemotherapy

Ongoing
2
334
Europe
Avastin, Aromasin, RO487-6646, Avastin, Aromasin, Avastin, Aromasin
ABCSG (Austrian Breast & Colorectal Cancer Study Group)
Postmenopausal women with histologically proven primary breast cancer of stages I-III scheduled for neoadjuvant endocrine treatment, N+/-, M0, HER2 negative; including patients with lobular breast cancer or patients with any breast cancer histology not suitable for chemotherapy or unlikely to respond to chemotherapy
 
 
NCT02007512 / 2013-002717-35: Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Active, not recruiting
2
247
Europe, Canada, US
Enzalutamide, MDV3100, XTANDI, exemestane, Aromasin, Placebo (for enzalutamide)
Pfizer, Astellas Pharma Inc, Medivation, Inc.
Breast Cancer
09/16
06/24
2015-005063-16: Different schedules of Exemestane in breast cancer women waiting for surgery Posologie variabili di exemestane in donne in postmenopausa con tumore alla mammella in attesa di intervento chirurgico

Ongoing
2
180
Europe
EXEMESTANE, [EXEMESTANE], Film-coated tablet
ISTITUTO EUROPEO DI ONCOLOGIA, MD ANDERSON
Postmenopausal ER positive breast cancer, waiting for surgery. Tumore della mammella ormono responsivo (stadio 0-II) in donne in postmenopausa in attesa di intervento chirurgico., Postmenopausal breast cancer patients waiting for surgery Tumore al seno in donne In postmenopausa in attesa di intervento chirurgico, Diseases [C] - Cancer [C04]
 
 
PREDIX LumA, NCT02592083: Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors

Active, not recruiting
2
10
Europe
Tamoxifen or Aromatase Inhibitor or Aromatase Inhibitor + goserelin, Tamoxifen, Letrozol or Anastrozol or Exemestane, Zoladex, Palbociclib, Ibrance
Thomas Hatschek
Early-Stage Breast Carcinoma, Hormone Receptor Positive Tumor
02/19
02/29
NCT02598557: Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer

Completed
2
180
Europe, US
Exemestane, Aromasin, FCE-24304, Laboratory Biomarker Analysis, Pharmacological Study, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Therapeutic Conventional Surgery
National Cancer Institute (NCI)
Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7
10/19
02/23
PRO30178, NCT03219476: Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

Active, not recruiting
2
37
US
Anastrozole, Arimidex, Letrozole, Femara, Exemestane, Aromasin, Tamoxifen, Soltamox
Medical College of Wisconsin
Breast Cancer, Invasive Breast Cancer
02/20
07/24
ChiCTR-OIC-17010440: The prospective, single-arm, single-center clinical study of Apatinib mesylate combined with Exemestane in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor

Not yet recruiting
2
30
 
Apatinib mesylate combined with Exemestane
The Affiliated Tumor Hospital of Guangxi Medical University; The Affiliated Tumor Hospital of Guangxi Medical University, Self-raised
Advanced breast cancer
 
 
2019-001447-40: A Short Course of a Daily Exemestane Tablet Before Surgery for Hyperplasia or Low Grade Cancer of the Endometrium Studio pilota con exemestane giornaliero in donne con iperplasia o tumore di basso grado dell'endometrio

Ongoing
2
40
Europe
Exemestane, [nd], Tablet, Aromasin
ENTE OSPEDALIERO OSPEDALI GALLIERA
Complex Atypical Hyperplasia of the Endometrium / Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer in post-menopausal women iperplasia atipica complessa dell’endometrio / neoplasia intraepiteliale dell’endometrio o tumore dell’endometrio di basso grado (grado 1 o grado 2) in donne in post menopausa, Pre cancerous lesion of endometrium/endometrial cancer Lesione precancerosa dell’endometrio/Tumore dell’endometrio, Diseases [C] - Cancer [C04]
 
 
PH002-TP-II, NCT03272477 / 2016-005157-21: Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients

Completed
2
257
Europe
Perjeta Injectable Product, Pertuzumab, Herceptin, Trastuzumab, Tamoxifen, Paclitaxel, Epirubicin, Cyclophosphamide, Anastrozole, Letrozole, Exemestane, Leuprorelin acetate, Goserelin, Leuporelin acetate, Biopsy, Surgery
Palleos Healthcare GmbH, Roche Pharma AG, WSG WOMEN´S HEALTHCARE STUDY GROUP, Cankado GmbH
Breast Neoplasms
07/20
03/24
2020-001984-10: A Study to Evaluate the Efficacy and Safety of GDC-9545 Compared with Physician's Choice of Endocrine Monotherapy in Patients with Previously Treated Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer

Not yet recruiting
2
300
Europe, RoW
GDC-9545, anastrozole, letrozole, exemestane, fulvestrant, Ro 719-7597/F12-01, RO0718807, Ro 489-7779, Ro 532-4663, Ro 320-8209, Capsule, Tablet, Coated tablet, Solution for injection, anastrozole, letrozole, exemestane, fulvestrant
F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd
Estrogen receptor (ER)-positive, HER2 negative locally advanced or metastatic breast cancer who have received one or two prior lines of systemic therapy in the locally advanced (recurrent or progressed) or metastatic setting, Breast cancer is cancer that develops from breast tissue, Hormone receptor (HR)-positive, HER2-negative breast cancer which tests positive for ER and negative for HER2, Diseases [C] - Cancer [C04]
 
 
2020-004909-32: Can treatment with Eribulin chemotherapy restore the sentivity in cancertissue in subsequent treatment with antihormon treatment? A study for patients with ER positive, HER2 normal breast cancer. Kan behandling med kemoterapien eribulin genskabe kræftvævets følsomhed for efterfølgende antihormonbehandling. Et studie til patienter med ER positiv, HER2 normal brystkræft.

Not yet recruiting
2
42
Europe
Halaven, Concentrate and solvent for solution for infusion, Tablet, Halaven, Aromasin
Department of Oncology, Department of oncology, University Hospital of Aarhus, Skejby
Metastatic breast cancer with estrogene positive and HER2 normal/negative subtype. Metastatisk brystkræft med østrogenreceptor positive og HER2 normal/negative HER2 receptor status., Breast cancer with has spred to other organs with is sentitive to estrogen and has a normal HER2 receptor status. Brystkræft med spredning til andre organer som er østrogen receptor positive og har HER2 normal udtryk ved immunhistokemi., Diseases [C] - Cancer [C04]
 
 
PREDIX LumB, NCT02603679: Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases

Active, not recruiting
2
181
Europe
Paclitaxel, Tamoxifen + Palbociclib, Tamoxifen, Ibrance, Aromatase Inhibitor + Palbociclib, Letrozole, Anastrozole, Exemestane, Goserelin + Aromatase Inhibitor + Palbociclib, Zoladex
Thomas Hatschek
Early-Stage Breast Carcinoma, Estrogen Receptor Positive Tumor
07/21
12/31
CLEAR, NCT03750396: Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer

Recruiting
2
110
RoW
Surgical resection, Stereotactic body radiotherapy, SBRT, Radiofrequency ablation, RFA
Gangnam Severance Hospital, Severance Hospital, Samsung Medical Center, Asan Medical Center
Breast Cancer, Recurrent Breast Cancer, Stereotactic Body Radiotherapy, Estrogen Receptor Positive Tumor, Her2-negative Tumor, Surgery
07/21
07/25
NCT04088110: Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

Not yet recruiting
2
77
RoW
Pyrotinib, Study drug, Trastuzumab, Herceptin®, Aromatase Inhibitors, anastrozole, letrozole or exemestane
Fuzhou General Hospital
Breast Cancer Female, HER2-positive Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Metastatic Breast Cancer, Breast Diseases, Hormone Receptor Positive Tumor
11/21
11/23
FATIMA, NCT02917005: PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer

Recruiting
2
160
RoW
Palbociclib, Ibrance, Exemestane, Aromasine, Goserelin, Zoladex
Hamdy A. Azim
Metastatic Breast Cancer
12/21
12/23
AMEERA-3, NCT04059484 / 2018-004593-98: Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer

Active, not recruiting
2
367
Europe, Canada, Japan, US, RoW
Amcenestrant, Fulvestrant, Faslodex®, Anastrozole, Arimidex®/Anastrozole Generics, Letrozole, Femara®/Letrozole Generics, Exemestane, Aromasin®/Exemestane Generics, Tamoxifen, Nolvadex®/Tamoxifen Generics
Sanofi
Breast Cancer Metastatic
02/22
09/24
NCT02648477: Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

Completed
2
30
US
Anastrozole, Arimidex, ICI D1033, ICI-D1033, ZD-1033, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Exemestane, Aromasin, FCE-24304, Laboratory Biomarker Analysis, Letrozole, CGS 20267, Femara, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
City of Hope Medical Center, National Cancer Institute (NCI), Merck Sharp & Dohme LLC
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
04/22
12/23
2021-002889-41: Reduction of hormone therapy duration in women with hormone-sensitive breast cancer at very low risk of metastatic recurrence

Not yet recruiting
2
696
Europe
letrozole, anastrozole, exemestane, Film-coated tablet, Tablet
UNICANCER, AGENDIA
Post-menopausal women with localized luminal A breast cancer and considered at low risk of metastatic relapse, Post-menopausal women with hormone-sensitive breast cancer at very low risk of metastatic recurrence, Diseases [C] - Cancer [C04]
 
 
NCT03910712: Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC

Not yet recruiting
2
250
NA
Pyrotinib, Study drug, Trastuzumab, Herceptin®, Aromatase inhibitor, anastrozole, letrozole or exemestane
Peking Union Medical College Hospital
Breast Cancer Female, HER2-positive Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Metastatic Breast Cancer, Breast Diseases, Hormone Receptor Positive Tumor
06/22
12/23
AMICA, NCT03555877: Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer

Completed
2
56
Europe
Ribociclib, Kisqali, Anastrozole, All marketed medicinal products with this active ingredient., Letrozole, Exemestane, Fulvestrant
German Breast Group
Breast Cancer Metastatic
07/22
07/22
NCT04129216: The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer

Completed
2
30
US
Tamoxifen Citrate, Soltamox, Letrozole, Femara, Exemestane, Aromasin, Blueprint, Mammaprint
Johns Hopkins University, Agendia
Breast Cancer
11/22
11/22
INGE-B, NCT02894398: Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant

Completed
2
388
Europe
Palbociclib, Ibrance, Letrozole, Femara, Anastrozole, Arimidex, Exemestane, Aromasin, Fulvestrant, Faslodex
iOMEDICO AG, Pfizer
Breast Cancer, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
02/23
02/23
NCT03300557: Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

Active, not recruiting
2
46
US
Exemestane, Aromasin, FCE-24304, Laboratory Biomarker Analysis, Pharmacokinetic Study, PHARMACOKINETIC, PK Study, Questionnaire Administration
National Cancer Institute (NCI)
Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
12/23
06/24
NCT04023292: Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer

Recruiting
2
185
RoW
Endocrine therapy, tamoxifen, Letrozole, Anastrazole, Exemestane, etc.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Neoplasms
07/23
07/25
POLLY, NCT02188745: ER Reactivation Therapy for Breast Cancer

Active, not recruiting
2
19
US
17B-estradiol, aromatase inhibitor, Letrozole, Letrozole (Aromatase inhibitor), Anastrozole, Aromatase inhibitor, Exemestane
Dartmouth-Hitchcock Medical Center
Metastatic Breast Cancer
04/24
10/24
NeoTEE, NCT04465097: Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer

Completed
2
30
RoW
Tucidinostat, Chidamide, Epidaza, Exemestane, Ovarian function suppression
First Affiliated Hospital, Sun Yat-Sen University
Breast Cancer
10/23
10/23
Breast52, NCT04272801: Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer

Active, not recruiting
2
83
US
tamoxifen, letrozole, anastrozole, or exemestane, Endocrine therapy, Patient reported outcomes, surveys, questionnaires
Shayna Showalter, MD
Breast Cancer Female
03/24
06/25
NCT05463601: Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer

Recruiting
2
132
RoW
Mecapegfilgrastim, dalpiciclib, exemestane, fulvestrant, letrozole, tamoxifen
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Jiangsu HengRui Medicine Co., Ltd.
Metastatic Breast Cancer
12/23
12/24
NCT05969184: Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC

Recruiting
2
94
RoW
CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou), Pertuzumab,Letrozole,exemestane
Peking University Cancer Hospital & Institute
Breast Neoplasm Female
12/23
12/24
ASPIRE, NCT03691493: Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis

Completed
2
38
US
Anastrozole, Arimidex, ICI D1033, ZD-1033, Exemestane, Aromasin, FCE-24304, Fulvestrant, Faslodex, ICI 182,780, ZD9238, Letrozole, CGS 20267, Femara, Palbociclib, Ibrance, PD-0332991, Radiation Therapy, Cancer Radiotherapy, Irradiation, Radiation, Radiotherapeutics, Tamoxifen, Soltamox, Nolvadex
Emory University, Pfizer, National Cancer Institute (NCI), National Institutes of Health (NIH)
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8
10/22
10/22
MCLA-128-CL02, NCT03321981 / 2017-002821-39: MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Completed
2
105
Europe, US
Zenocutuzumab, MCLA-128, Trastuzumab, Herceptin, Vinorelbine, Navelbine, vinorelbine tartrate, Endocrine therapy, fulvestrant, exemestane, letrozole, anastrazole
Merus N.V.
Breast Cancer Metastatic
10/22
07/23
METALLICA, NCT04300790: Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients

Active, not recruiting
2
69
Europe
Alpelisib, BYL719, Metformin, Fulvestrant, Letrozole, Exemestane, Vildagliptin, Tamoxifen
MedSIR, Novartis
Breast Cancer
03/25
06/26
NCT06149130: Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer

Recruiting
2
82
RoW
Adebrelimab, SHR-1316, dalpiciclib, SHR-6390
Tongji Hospital
Breast Cancer
11/25
11/26
NRG-GY033, NCT06169124: Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors

Suspended
2
37
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Chest Radiography, Chest X-ray, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, Exemestane, Aromasin, FCE-24304, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Luprodex Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI), NRG Oncology
Adult Ovarian Granulosa Cell Tumor
05/27
05/27
NCT05079360: Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

Withdrawn
2
200
US
Sabizabulin, Veru-111, Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator, exemestane
Veru Inc.
Metastatic Breast Cancer
03/24
05/24
NCT05411380: Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

Recruiting
2
73
RoW
Tucidinostat, Chidamide, Capecitabine, Xeloda, Endocrine Therapy, Anastrozole, Letrozole, Exemestane, Fulvestrant
wang shusen
Breast Cancer
04/24
04/25
NCT04858516: Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer

Not yet recruiting
2
57
NA
palbociclib and exemestane plus trastuzumab and pyrotinib
Guangdong Provincial People's Hospital
Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
04/24
04/25
CAMERAN, NCT05472792: Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65

Recruiting
2
90
US
Accelerated Partial Breast Irradiation (APBI), tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene
UNC Lineberger Comprehensive Cancer Center
Breast Cancer, Quality of Life
04/27
04/32
LITESPARK-029, NCT06428396: Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/)

Not yet recruiting
2
120
NA
Belzutifan, MK-6482, Fulvestrant, Everolimus, Exemestane
Merck Sharp & Dohme LLC
Metastatic Breast Cancer
06/27
05/28
NCT06179303: Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Not yet recruiting
2
60
US
Abemaciclib, LY-2835219, LY2835219, Verzenio, Anastrozole, Anastrazole, Arimidex, ICI D1033, ICI-D1033, ZD-1033, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Diagnostic Imaging, Medical Imaging, Exemestane, Aromasin, FCE-24304, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Fluorine F 18 Fluoro Furanyl Norprogesterone, [18F]FFNP, Fulvestrant, Faslodex, Faslodex(ICI 182,780), ICI 182,780, ICI 182780, ZD9238, Gonadotropin-releasing Hormone Analog, GnRH Agonist, GnRH Analog, Gonadotropin-Releasing Hormone Agonist, Gonadotropin-Releasing Hormone Analogue, LH-RH agonist, LH-RH Analogs, LHRH Agonist, luteinizing hormone-releasing hormone agonist, Luteinizing Hormone-Releasing Hormone Analog, Letrozole, CGS 20267, Femara, Fempro, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Tamoxifen, TMX, Therapeutic Estradiol, 17 Beta-Estradiol, Aquadiol, Climara, Dimenformon, Diogyn, Diogynets, Estrace, ESTRADIOL, Estraldine, Oestradiol, Ovocylin, Progynon, Vagifem
University of Washington, Breast Cancer Research Foundation
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma, Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
03/25
06/26
NCT03179904: TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Active, not recruiting
2
19
US
Anastrozole, Anastrazole, Arimidex, ICI D1033, ICI-D1033, ZD-1033, Denifanstat, ASC 40, ASC-40, ASC40, FASN Inhibitor TVB-2640, TVB 2640, TVB-2640, TVB2640, Exemestane, Aromasin, FCE-24304, Fulvestrant, Faslodex, Faslodex(ICI 182,780), ICI 182,780, ICI 182780, ZD9238, Echocardiography, EC, Letrozole, CGS 20267, Femara, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Trastuzumab, 180288-69-1, ABP 980, ALT02, Biceltis, CANMab, CT-P06, CT-P6, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herclon, Hertraz, Herzuma, Immunoglobulin G 1 (Human-Mouse Monoclonal RhuMab HER2gamma1-Chain Antihuman p185(Sup c-erbB2) Receptor), Disulfide with Human-Mouse Monoclonal RhuMab HER2 Light Chain, Dimer, Kanjinti, Ogivri, Ontruzant, PF-05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, Trastuzumab Biosimilar CT-P6, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trazimera, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, computerized axial tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT SCAN, tomography, Magnetic Resonance Imaging, MRI, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI Scan, MRIs, NMRI, nuclear magnetic resonance imaging, sMRI, Structural MRI, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Biopsy, BIOPSY_TYPE, Bx
Mayo Clinic, National Cancer Institute (NCI)
Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, HER2-positive Breast Cancer
07/24
07/24
BabyTears, NCT06364267: Low Dose Tamoxifen vs Low Dose Exemestane in Post-menopausal Women at High Risk for Breast Cancer.

Not yet recruiting
2
160
Europe
Tamoxifen 10 MG, Exemestane 25 MG
Andrea DeCensi, Dana-Farber/Brigham and Women's Cancer Center, Herbert Irving Comprehensive Cancer Center, Istituto Europeo di Oncologia, Breast Cancer Research Foundation
Breast Cancer
09/26
09/26
ZYYY-BC-001, NCT04997798: Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer

Recruiting
2
30
RoW
Trastuzumab Pyrotinib Exemestane Dalpiciclib, Herceptin Pyrotinib Aromasin Dalpiciclib
First Affiliated Hospital of Zhejiang University
Breast Cancer, Estrogen Receptor Positive Tumor, HER2-positive Breast Cancer
12/24
12/24
RaPhLRR, NCT05467891: Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

Recruiting
2
200
US
Ribociclib, Kisqali, Fulvestrant, Faslodex, Anastrozole, Arimidex, Letrozole, Femara, Exemestane, Aromasin
Oana Danciu, Novartis Pharmaceuticals
Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
12/24
12/27
BFR-ESS, NCT03624244: Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)

Recruiting
2
40
Europe
Aromatase Inhibitors, ANASTRAZOLE, ARIMIDEX, AROMASINE, EXEMESTANE, FEMARA, LETROZOLE
Centre Leon Berard
Low Grade Endometrial Stromal Sarcoma
01/25
01/28
NCT02476786: Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

Recruiting
2
50
US
FACT-B, Goserelin, Goserelin acetate, Zoladex, Anastrozole, Arimidex®, Exemestane, Aromasin®, Fulvestrant, Faslodex®, Tamoxifen, Nolvadex®, Archived tissue collection
Washington University School of Medicine, Genomic Health®, Inc.
Breast Cancer, Cancer of Breast, Breast Neoplasms, Cancer of the Breast
07/25
01/30
BCTOP-L-M05, NCT05594095: SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Recruiting
2
140
RoW
PIK3CA inhibitor, AKT inhibitor, Carrelizumab, SHR1210, Famitinib, Fluzoparib, SHR3162, Dalpiciclib, SHR6390, SHR-A1811, TROP2 ADC, Everolimus, Aromatase Inhibitors or Fulvestrant, Goserelin, TPC, RTK Inhibitor
Fudan University, Peking University Cancer Hospital & Institute, First Hospital of China Medical University, Sun Yat-sen University, First Affiliated Hospital Xi'an Jiaotong University, Chongqing University Cancer Hospital, Northern Jiangsu People's Hospital, Fujian Medical University Union Hospital, Ningbo Medical Center Lihuili Hospital, Shanghai First Maternity and Infant Hospital, Shanghai 6th People's Hospital, Affiliated Hospital of Nantong University
Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer, Advanced Breast Cancer
12/25
12/26
NCT05872347: Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

Recruiting
2
52
RoW
SPH4336 Tablets
Shanghai Pharmaceuticals Holding Co., Ltd
Breast Cancer Brain Metastases
12/25
12/25
TRADE, NCT06001762: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

Recruiting
2
90
US
Abemaciclib, Tamoxifen, Anastrozole, Letrozole, Exemestane, LHRH Agonist
Dana-Farber Cancer Institute, Eli Lilly and Company
Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma
01/26
01/27
EVANGELINE, NCT05607004: (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

Recruiting
2
180
US
(Z)-endoxifen, endoxifen, exemestane, Aromasin, goserelin, Zoladex
Atossa Therapeutics, Inc., InClin
Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer
02/26
09/26
NCT05861271: Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer

Recruiting
2
1008
RoW
Capecitabine，Pyrotinib, Pyrotinib
Fudan University
Breast Cancer Stage I
07/26
07/28
BCTOP-L-M01, NCT05949541: Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer

Recruiting
2
265
RoW
Everolimus 10 mg, Afinitor, CDK4/6 Inhibitor SHR6390, Dalpiciclib, Aromatase inhibitor and Fulvestrant combined with CDK4/6 inhibitors, Endocrine therapy
Fudan University
Breast Cancer, Advanced Breast Cancer
07/26
01/28
NCT05826964: Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Recruiting
2
500
US
AI+CDK4/6i, Aromatase Inhibitor (AI) + Cyclin dependent kinase 4 and 6 inhibitor (CDK4/6i), Anastrozole, Letrozole, Exemestane, Palbociclib, Ribociclib, Abemaciclib, SERD+CDK4/6i, Selective Estrogen Receptor Degrader (SERD) + CDK4/6i, Fulvestrant, mTOR inhibitor + AI, Mammalian target of rapamycin (mTOR) inhibitor + Aromatase Inhibitor (AI), Everolimus, mTOR inhibitor + SERD, mTOR inhibitor + Selective estrogen receptor modulator, Tamoxifen, PI3K inhibitor + SERD, Phosphoinositide 3-kinase (PI3K) inhibitor + SERD, Alpelisib, PI3K inhibitor + AI, Chemotherapy, Taxane, Eribulin, Capecitabine, Vinorelbine, Oral SERD, Elacestrant
University of Miami
Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
07/26
07/29
ADEPT, NCT04569747: A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

Recruiting
2
375
US
Pertuzumab+TRASTUZUMAB, PHESGO, ADJUVANT ENDOCRINE THERAPY, Letrozole, Anastrozole, Exemestane, Tamoxifen, Leuprolide, or other LHRH agonist (per investigator discretion)
Dana-Farber Cancer Institute, Genentech, Inc.
HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
09/26
09/30
NCT05150652: Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

Recruiting
2
70
US
Anastrozole 1mg, Arimidex, Letrozole 2.5mg, Femara, Exemestane 25 mg, Aromasin, Tamoxifen, Soltamox
Veronica Morgan Jones
Breast Cancer, HER2-negative Breast Cancer, Node-negative Breast Cancer, Breast Carcinoma
10/26
10/36
TRAK-ER, NCT04985266: A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer

Recruiting
2
1100
Europe
Palbociclib 125Mg Tab, Fulvestrant injection, Tamoxifen, Letrozole, Exemestane, Anastrozole
Royal Marsden NHS Foundation Trust, Pfizer, AstraZeneca, Institute of Cancer Research, United Kingdom, UNICANCER, Gustave Roussy, Cancer Campus, Grand Paris, Invitae Corporation
ER+ Breast Cancer, HER2-negative Breast Cancer
09/27
09/30
NCT06075953: DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Recruiting
2
400
US
Tamoxifen, Exemestane, Letrozole, Anastrazole, Testosterone + Anastrazole, T+Ai, Elacestrant, Z-endoxifen
QuantumLeap Healthcare Collaborative
Ductal Carcinoma in Situ
11/28
11/33
PEER, NCT02990845: Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer

Terminated
1/2
16
RoW
Pembrolizumab/ Exemestane/ Leuprolide
National Taiwan University Hospital, Merck Sharp & Dohme LLC
Premenopausal Breast Cancer
08/22
08/22
NCT06431243: A Clinical Study of Puesta Mesylate for Injection in Patients With Solid Tumors

Not yet recruiting
1/2
120
RoW
A group Purinostat Mesylate 6mg/m2, A group Purinostat Mesylate 8.4mg/m2, A group Purinostat Mesylate 11.2mg/m2, A group Purinostat Mesylate 15.0mg/m2, B group Purinostat Mesylate 6.0mg/m2, B group Purinostat Mesylate 8.4 mg/m2, B group Purinostat Mesylate 11.2 mg/m2, B group Purinostat Mesylate 15.0 mg/m2
Chengdu Zenitar Biomedical Technology Co., Ltd
Advanced Solid Tumor
05/26
11/26
MORPHEUS, NCT03280563: A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Active, not recruiting
1/2
138
US, RoW
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody, Tecentriq, Bevacizumab, Avastin, Entinostat, Exemestane, Fulvestrant, Ipatasertib, Tamoxifen, Abemaciclib
Hoffmann-La Roche
Breast Neoplasms
12/24
12/24

Download Options